BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

556 related articles for article (PubMed ID: 11053905)

  • 21. In-vitro antifungal activity of liposomal nystatin in comparison with nystatin, amphotericin B cholesteryl sulphate, liposomal amphotericin B, amphotericin B lipid complex, amphotericin B desoxycholate, fluconazole and itraconazole.
    Carrillo-Muñoz AJ; Quindós G; Tur C; Ruesga MT; Miranda Y; del Valle O; Cossum PA; Wallace TL
    J Antimicrob Chemother; 1999 Sep; 44(3):397-401. PubMed ID: 10511410
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Susceptibility testing of Cryptococcus diffluens against amphotericin B, flucytosine, fluconazole, itraconazole, voriconazole and posaconazole.
    Kantarcioğlu AS; Boekhout T; Yücel A; Altas K
    Med Mycol; 2009 Mar; 47(2):169-76. PubMed ID: 18654925
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Antifungal drug resistance in pathogenic fungi.
    Vanden Bossche H; Dromer F; Improvisi I; Lozano-Chiu M; Rex JH; Sanglard D
    Med Mycol; 1998; 36 Suppl 1():119-28. PubMed ID: 9988500
    [TBL] [Abstract][Full Text] [Related]  

  • 24. In vitro activities of posaconazole, fluconazole, itraconazole, voriconazole, and amphotericin B against a large collection of clinically important molds and yeasts.
    Sabatelli F; Patel R; Mann PA; Mendrick CA; Norris CC; Hare R; Loebenberg D; Black TA; McNicholas PM
    Antimicrob Agents Chemother; 2006 Jun; 50(6):2009-15. PubMed ID: 16723559
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Post-antifungal effect and adhesion to buccal epithelial cells of oral Candida dubliniensis isolates subsequent to limited exposure to amphotericin B, ketoconazole and fluconazole.
    Ellepola AN; Chandy R; Khan ZU
    J Investig Clin Dent; 2015 Aug; 6(3):186-92. PubMed ID: 24850753
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Comparative evaluation of PASCO and national committee for clinical laboratory standards M27-A broth microdilution methods for antifungal drug susceptibility testing of yeasts.
    Arthington-Skaggs BA; Motley M; Warnock DW; Morrison CJ
    J Clin Microbiol; 2000 Jun; 38(6):2254-60. PubMed ID: 10834985
    [TBL] [Abstract][Full Text] [Related]  

  • 27. In-vitro activity of five antifungal agents against uncommon clinical isolates of Candida spp.
    Barchiesi F; Tortorano AM; Di Francesco LF; Cogliati M; Scalise G; Viviani MA
    J Antimicrob Chemother; 1999 Feb; 43(2):295-9. PubMed ID: 11252339
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Impact of brief and sequential exposure to nystatin, amphotericin B, ketoconazole, and fluconazole in modulating adhesion traits of oral Candida dubliniensis isolates.
    Ellepola AN; Joseph BK; Samaranayake LP; Bandara HM; Khan ZU
    J Investig Clin Dent; 2016 May; 7(2):149-57. PubMed ID: 25388637
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Candida spp. in vitro susceptibility profile to four antifungal agents. Resistance surveillance study in Venezuelan strains.
    Panizo MM; Reviákina V; Dolande M; Selgrad S
    Med Mycol; 2009 Mar; 47(2):137-43. PubMed ID: 18651308
    [TBL] [Abstract][Full Text] [Related]  

  • 30. [INVESTIGATION ON ANTIFUNGAL SUSCEPTIBILITY OF CANDIDA YEASTS IN PREGNANT PATIENTS WITH CONFIRMED VULVOVAGINAL CANDIDIASIS AND THEIR NEWBORNS.].
    Chokoeva A; Kouzmanov A; Ivanova Z; Zisova L; Amalie G; Petleshkova P; Miteva-Katrandzhieva T; Krasteva M; Uchikova E
    Akush Ginekol (Sofiia); 2016; 55(4):20-29. PubMed ID: 29370489
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Fluconazole exposure rather than clonal spreading is correlated with the emergence of Candida glabrata with cross-resistance to triazole antifungal agents.
    Chen TC; Chen YH; Chen YC; Lu PL
    Kaohsiung J Med Sci; 2012 Jun; 28(6):306-15. PubMed ID: 22632885
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Candida and candidaemia. Susceptibility and epidemiology.
    Arendrup MC
    Dan Med J; 2013 Nov; 60(11):B4698. PubMed ID: 24192246
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Oral Candida isolates among HIV-infected subjects in Nigeria.
    Nweze EI; Ogbonnaya UL
    J Microbiol Immunol Infect; 2011 Jun; 44(3):172-7. PubMed ID: 21524610
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Detection of Candida dubliniensis in oropharyngeal samples from human immunodeficiency virus-infected patients in North America by primary CHROMagar candida screening and susceptibility testing of isolates.
    Kirkpatrick WR; Revankar SG; Mcatee RK; Lopez-Ribot JL; Fothergill AW; McCarthy DI; Sanche SE; Cantu RA; Rinaldi MG; Patterson TF
    J Clin Microbiol; 1998 Oct; 36(10):3007-12. PubMed ID: 9738058
    [TBL] [Abstract][Full Text] [Related]  

  • 35. In vitro activities of voriconazole and five licensed antifungal agents against Candida dubliniensis: comparison of CLSI M27-A2, Sensititre YeastOne, disk diffusion, and Etest methods.
    Salgado-Parreño FJ; Alcoba-Flórez J; Arias A; Moragues MD; Quindós G; Pontón J; Arévalo MP
    Microb Drug Resist; 2006; 12(4):246-51. PubMed ID: 17227209
    [TBL] [Abstract][Full Text] [Related]  

  • 36. [In vitro activity of fluconazole, voriconazole and posaconazole against Candida spp].
    Rubio Calvo MC; Gil J; Ramírez de Ocáriz I; Benito R; Rezusta A
    Rev Esp Quimioter; 2003 Jun; 16(2):227-32. PubMed ID: 12973462
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Impact of short-term exposure of antifungal agents on hemolysin activity of oral Candida dubliniensis isolates from Kuwait and Sri Lanka.
    Ellepola AN; Jayathilake JA; Sharma PN; Khan ZU
    J Investig Clin Dent; 2016 Nov; 7(4):424-430. PubMed ID: 26059506
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Antifungal susceptibility of Candida biofilms: unique efficacy of amphotericin B lipid formulations and echinocandins.
    Kuhn DM; George T; Chandra J; Mukherjee PK; Ghannoum MA
    Antimicrob Agents Chemother; 2002 Jun; 46(6):1773-80. PubMed ID: 12019089
    [TBL] [Abstract][Full Text] [Related]  

  • 39. In vitro susceptibility of 545 isolates of Candida spp. to four antifungal agents.
    Arias A; Arévalo MP; Andreu A; Rodríguez C; Sierra A
    Mycoses; 1994; 37(7-8):285-9. PubMed ID: 7739661
    [TBL] [Abstract][Full Text] [Related]  

  • 40. In vitro activities of voriconazole (UK-109, 496), fluconazole, itraconazole and amphotericin B against 132 non-albicans bloodstream yeast isolates (CANARI study).
    Swinne D; Watelle M; Van der Flaes M; Nolard N
    Mycoses; 2004 Jun; 47(5-6):177-83. PubMed ID: 15189180
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 28.